Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin - A preliminary report

Clinical Rheumatology

Volumn 19, Issue 3, 2000, Pages 207-211

  Levy, Y ^a   Sherer, Y ^a   Langevitz, P ^b   Lorber, M ^c   Rotman, P ^a   Fabrizzi, F ^d   Shoenfeld, Yehuda ^a,e  

^a Research Unit of Autoimmune Diseases   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c RAMBAM MEDICAL CENTER   (Israel)

^d Clinical Trial Consultant   (Italy)

^e SHEBA MEDICAL CENTER   (Israel)

Author keywords

Autoimmunity; Intravenous immunoglobulin; Renal crisis; Scleroderma; Skin score

Indexed keywords

IMMUNOGLOBULIN;

ADULT; ARTICLE; CASE REPORT; DRUG MEGADOSE; FEMALE; HUMAN; IMMUNOTHERAPY; MALE; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME;

ADULT; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SKIN; TREATMENT OUTCOME;

EID: 0034038720     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100670050158     Document Type: Article

References (38)

1. Kazatchkine MD, Morell A. Intravenous immunoglobulin research and therapy. New York: Parthenon Publishing, 1996.
2. Krause I, Blank M, Kopolovic J, et al. Abrogation of experimental systemic lupus erythematosus and primary antiphospholipid syndrome with intravenous gamma globulin. J Rheumatol 1995;22:1068-74.
3. Tomer Y, Shoenfeld Y. Successful treatment of psychosis secondary to SLE with high dose intravenous immunoglobulin. Clin Exp Rheumatol 1992;10:391-3.
4. Bakimer R, Guilburd B, Zurgil N, Shoenfeld Y. The effect of intravenous γ-globulin on the induction of experimental antiphospholipid syndrome. Clin Immunol Immunopathol 1993:69:97-102.
5. Shoenfeld Y, Krause I, Blank M. New methods of treatment in an experimental murine model of systemic lupus erythematosus induced by idiotypic manipulation. Ann Rheum Dis 1997;56:5-11.
6. Winder A, Shoenfeld Y, Hochman R, Keren G, Levy Y, Eldor A. High dose intravenous gammaglobulin for heparin induced thrombocytopenia: a prompt response. J Clin Immunol. 1998;18:330-4.
7. Shoenfeld Y, Krause I. Immunosuppression and immunomodulation of experimental systemic lupus erythematosus and antiphospholipid syndrome. Transplant Proc 1996;28:3096-8.
8. Corvetta A, Della Bitta R, Gabrielli A, Spaeth PJ, Danieli G. Use of high-dose intravenous immunoglobulin in systemic lupus erythematosus: report of three cases. Clin Exp Rheumatol 1989;7:295-9.
9. Levy Y, Sherer Y, George J, et al. Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin. Int Arch Allergy Immunol 1999;119:231-8.
10. Schroeder JO, Zeuner RA, Euler HH, Loffler H. High dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study. J Rheumatol 1996;23:71-5.
11. Aharon A, Levy Y, Bar-Dayan Y, et al. Successful treatment of early secondary myelofibrosis in SLE with IVIG. Lupus 1997;6:408-11.
12. Clements P, Lachenbruch P, Siebold J, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
13. Furst DE, Clements PJ, Steen VD, et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998;25:84-8.
14. Biasi D, Carletto A, Caramaschi P, et al. Iloprost as cyclic five-day infusions in the treatment of scleroderma. An open pilot study in 20 patients treated for one year. Rev Rhum Engl Ed 1998;65:745-50.
15. Mizutani H, Yoshida T, Nouchi N, Hamanaka H, Shimizu M. Topical tocoretinate improved hypertrophic scar, skin sclerosis in systemic sclerosis and morphea. J Dermatol 1999;26:11-17.
16. Grassegger A, Schuler G, Hessenberger G, et al. Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial. Br J Dermatol 1998;139:639-48.
17. Martini A, Maccario R, Ravelli A, et al. Marked and sustained improvement two years after autologous stem cell transplantation in a girl with systemic sclerosis. Arthritis Rheum 1999;42:807-11.
18. Ben-Chetrit E, Levy M. Colchicine: 1998 update. Semin Arthritis Rheum 1998;28:48-59.
19. Clements PJ, Furst DE, Wong WK, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999;42:1194-203.
20. Arnett FC. HLA and autoimmunity in scleroderma (systemic sclerosis). Int Rev Immunol 1995;12:107-28.
21. Dwyer E, Winchester R. The role of the trimolecular complex (αβTCR-MHC+peptide) in the pathogenesis of systemic sclerosis. In: Korn J, LeRoy C, eds. The immunopathogenesis of systemic sclerosis. Int Rev Immunol 1995;12:85-96.
22. White B. Immunopathogenesis of systemic sclerosis. Rheum Dis Clin North Am 1996;22:695-708.
23. Fleishmajer R, Perlish JS, Reeves JRT. Cellular infiltrates in scleroderma skin. Arthritis Rheum 1977;20:975.
24. Marks RM, Czerniecki M, Andrews BS, et al. The effects of scleroderma serum on human microvascular endothelial cells. Induction of antibody-dependent cellular cytotoxicity. Arthritis Rheum 1988;31:1524-34.
25. White B. Immune pathogenesis. In: Clements P, Furst D, eds. Systemic sclerosis. Malvern, PA: Lea & Febiger, 1996:229-50.
26. Piguet PF, Vesin C, Grau GE, Thompson RC. Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine 1993;5:57-61.
27. Tenser RB, Hay KA, Aberg JA. Immunoglobulin G immunosuppression of multiple sclerosis. Suppression of all three major lymphocyte subsets. Arch Neurol 1993;50:417-20.
28. Kaveri S, Vassilev T, Hurez V, et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 1996;97:865-9.
29. van Shaik IN, Lundkvist I, Vermeulen M, Brand A. Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vivo. J Clin Immunol 1992;12:325-34.
30. Aukrust P, Muller F, Nordoy I, et al. Modulation of lymphocyte and monocyte activity after intravenous immunoglobulin administration in vivo. Clin Exp Immunol 1997;107:50-6.
31. Klaesson S, Tammik L, Markling L, et al. Inhibition of immunoglobulin production in vitro by IgG and F(ab')2 fragments, but not the Fc portion. Scand J Immunol 1996;43:574-82.
32. Miletic VD, Hester CG, Frank MM. Regulation of complement activity by immunoglobulin. I. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes. J Immunol 1996;156:749-57.
33. Basta M. Modulation of complement-mediated immune damage by intravenous immune globulin. Clin Exp Immunol 1996;104 (Suppl 1):21-5.
34. Toyoda M, Zhang X, Petrosian A, et al. Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin. J Clin Immunol 1994;14:178-89.
35. Amran D, Renz H, Lack G, et al. Suppression of cytokinedependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 1994;73:180-6.
36. Ruiz de Souza V, Carreno MP, Kaveri SV, et al. Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by polyspecific IgG (intravenous immunoglobulin). Eur J Immunol 1995;25:1267-73.
37. Andersen LS, Petersen J, Svenson M, Bendtzen K. IgG for intravenous use, autologous serum and plasma induce comparable interleukin-1 receptor antagonist liberation from human mononuclear cells: an in vitro phenomenon depending upon plastic adherence. Autoimmunity 1995;22:127-33.
38. Sherer Y, Shoenfeld Y. Stem cells transplantation - a cure for autoimmune diseases. Lupus 1998;7:137-40.